N/A N=16,801 Randomized Prevention

Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage

Triage · Risk Stratification With Biomarker

Bottom Line

View on ClinicalTrials.gov: NCT02643459 ↗

Enrolled (actual)

16,801

Serious AEs

0.0%

Results posted

Mar 2021

Primary outcome: Primary: All Cause Mortality — 1126; 1241 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: suPAR measurement (Behavioral)
Age: Pediatric, Adult, Older Adult · 16+ yrs
Sex: All
Sponsor: Herlev Hospital
Primary completion: Apr 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY All Cause Mortality	319; 359	—
SECONDARY All Cause Mortality	319; 359	—
SECONDARY Number of Discharges From the Emergency Room Within 24 Hours	3934; 4352	—
SECONDARY Number of Admissions to the Medical Ward	3500; 3738	—
SECONDARY Number of Patients With an Admission to the Intensive Care Unit	1027; 1157	—
SECONDARY Number of Patients With New Cancer Diagnosis in Control vs Intervention Groups	687; 917	—
SECONDARY Length of Stay During Admission.	4.53; 4.39	—
SECONDARY Number of Readmissions	687; 917	—

Summary

Will clinical outcome for patients be improved if triage in Acute wards and Emergency rooms is supplemented with a prognostic biomarker?

Eligibility Criteria

Inclusion Criteria

Patients presenting acutely to the Acute ward/Emergency department and have blood samples done which include both Hemoglobin, C reactive protein and Creatinine within 6 hours of registration within the study period. The study is carried out in 2 Hospitals in the Capital of Denmark.

Exclusion Criteria

Patients presenting in Pediatric, Gynecological or Obstetric units. Patients not being examined with blood samples.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02643459). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.